News | February 10, 2025
Wockhardt posts Q3 net profit at Rs. 20 Cr
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
EBITDA margins expand to 31.3%
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The 254-bedded Aster Aadhar Hospital, Kolhapur is the city's most comprehensive multi-speciality hospital
The product is expected to be launched in Q3FY25
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The product is used to treat amyotrophic lateral sclerosis
Subscribe To Our Newsletter & Stay Updated
